StreetInsider.com News Articles

Form 6-K Polyrizon Ltd. For: Jun 17

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659718.html

Form 6-K Polyrizon Ltd. For: Jun 17

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659718.html

Polyrizon patent application for nasal drug delivery platform published in U.S.

Wed, 17 Jun 2026 08:16:18 -0400

Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotech company based in Raanana, Israel, announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery."

The application covers the company's Trap & Target mucoadhesive polymer technology platform, which is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa. According to the company, the technology aims to increase formulation retention, improve drug absorption, and enable delivery of active pharmaceutical ingredients through the nasal route.

The application describes biocompatible mucoadhesive compositions that combine sulfated polysaccharides with hydrophilic polymers, partially crosslinked with divalent ions. The resulting formulations

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Wed, 17 Jun 2026 08:15:00 -0400

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Wed, 17 Jun 2026 08:15:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 15

Mon, 15 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260615/26647144.html

Form 6-K Polyrizon Ltd. For: Jun 15

Mon, 15 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260615/26647144.html

Polyrizon initiates human study for NASARIX allergy blocker

Mon, 15 Jun 2026 08:05:37 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced it has executed agreements with a European university medical center and a clinical research organization to conduct a human study evaluating the nasal residence time of its NASARIX allergy blocker.

The study will measure how long the NASARIX formulation remains in the nasal cavity following administration, which the company states is intended to support estimation of the product's potential duration of protective barrier function.

The investigation is structured as a performance and characterization study rather than an interventional clinical trial focused on safety or efficacy. The study forms part of Polyrizon's verification and validation activities and is

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Mon, 15 Jun 2026 08:05:00 -0400

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the execution of an agreement with a leading, internationally recognized European university medical center, alongside a contract with a specialized clinical research organization (CRO), to conduct a human study as part of its verification and validation (V&V) program for

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Mon, 15 Jun 2026 08:05:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 10

Wed, 10 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260610/26629701.html

Form 6-K Polyrizon Ltd. For: Jun 10

Wed, 10 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260610/26629701.html

Polyrizon receives European patent publication for nasal drug delivery tech

Wed, 10 Jun 2026 07:47:20 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced that the European Patent Office has published the company's patent application for mucoadhesive nasal drug delivery technology. The application, titled "Mucoadhesive Polymers for Nasal Drug Delivery," was published under European publication number EP 4751737.

The patent application covers Polyrizon's Trap & Target mucoadhesive polymer technology platform, which is designed to enhance interaction between pharmaceutical formulations and nasal mucosa. The technology aims to increase formulation retention and improve drug absorption through nasal administration.

"The forthcoming publication of this European patent application marks an important step in strengthening our position in the growing nasal drug delivery market," said Tomer

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Wed, 10 Jun 2026 07:47:00 -0400

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application entitled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application was published under European publication number EP 4751737. The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Wed, 10 Jun 2026 07:47:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 08

Mon, 08 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260608/26617093.html

Form 6-K Polyrizon Ltd. For: Jun 08

Mon, 08 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260608/26617093.html

Form 6-K Polyrizon Ltd. For: Jun 08

Mon, 08 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260608/26617100.html

Form 6-K Polyrizon Ltd. For: Jun 08

Mon, 08 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260608/26617100.html

Polyrizon secures three US sites for NASARIX allergy trial

Mon, 08 Jun 2026 09:31:10 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced it has signed agreements with two additional U.S. clinical sites, bringing the total to three contracted sites for its upcoming NASARIX clinical study. The biotech company said these sites will participate in a multi-center trial evaluating the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis.

The study is titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis" and is designed as a multi-center trial in the United States, with up to five clinical sites expected to

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Mon, 08 Jun 2026 09:25:00 -0400

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study.

These three sites represent the largest and most strategically important centers in the Company’s planned multi-center clinical trial and are expected to contribute the highest rates of patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Mon, 08 Jun 2026 09:25:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 05

Fri, 05 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26610878.html

Form 6-K Polyrizon Ltd. For: Jun 05

Fri, 05 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26610878.html

Form 6-K Polyrizon Ltd. For: May 27

Wed, 27 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260527/26558284.html